SK Hynix vs Tilray Brands Inc — how do they compare? SK Hynix trades at $193 (market cap $945.90B), while Tilray Brands Inc trades at $4.21 (market cap $591.60M). The key difference: SK Hynix is far larger — about 1598.9× Tilray Brands Inc's market cap, and SK Hynix is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| SKHY | TLRY | |
|---|---|---|
Market Cap | $945.90B | $591.60M |
Sector | Technology | Health |
52-Week High | $198.63 | $21.00 |
52-Week Low | $126.79 | $3.88 |
Enterprise Value | $896.20B | $758.73M |
Signals from Pluang's Aura AI — not financial advice
SKHY trades at $185.55, up 4.83% today, with strong fundamental performance including 85.62% net income margin and consistent earnings beats. The stock shows neutral technical signals near pivot point $186, with support at $183 and resistance at $189. Recent news highlights SKHY's leadership in AI memory chips with 50% HBM market share and strong demand from AI infrastructure buildout.
Outlook remains positive with 100% analyst buy ratings and $248 consensus price target representing 34% upside. Key risks include memory cycle volatility and competitive pressures, but strong HBM positioning and expanding AI partnerships provide growth catalysts. Revenue growth accelerated to 85.61% profit margin in 2026 trends.
TLRY trades at $4.30, down 4.44% today, reflecting ongoing investor skepticism despite record fiscal 2026 revenue of $915 million. The stock shows bearish technical signals with key support at $4.00, while fundamentals reveal significant challenges including negative net income margins (-13.26%) and consecutive earnings misses. Recent developments include strategic partnerships expansion in New York and California spirits markets and increased medical cannabis production capacity to 275 metric tonnes.
TLRY faces substantial execution risks with persistent losses and negative cash flow, though trading below book value (P/B 0.37) offers potential value. Analyst consensus remains cautious with 65% hold ratings, while regulatory progress in cannabis remains a key catalyst. The stock requires successful margin improvement and U.S. regulatory clarity for sustained recovery.
Trailing returns across standard periods
Latest headlines on both assets
SK hynix is a South Korean semiconductor company that manufactures memory products, including DRAM and NAND flash. Its high-bandwidth memory (HBM) products are designed for high-performance computing and AI applications.
Read more on SKHY →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →